Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8080MR)

This product GTTS-WQ8080MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8080MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8363MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ2793MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ9984MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ4522MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ5616MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ15452MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ9209MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ15544MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW